Effect of Pantoprazole Versus Other Proton Pump Inhibitors on 24-hour Intragastric pH and Basal Acid Output in Zollinger-Ellison Syndrome

Gastroenterol Clin Biol. 2002 Apr;26(4):355-9.

Abstract

Aim: In this open prospective study, the efficacy of pantoprazole in reducing gastric acid secretion in Zollinger-Ellison syndrome patients was compared to that obtained previously with other proton pump inhibitors.

Methods: Eleven male patients previously treated with omeprazole (n=7, mean dosage: 63 mg/day; range: 20-100 mg/day) or lansoprazole (n=4, mean dosage: 75 mg/day; range: 30-120 mg/day) were included. These patients underwent a 24-hour intragastric pH-metry, measurement of basal acid output and of serum gastrin first while receiving their usual therapy and second after 7 to 10 days of pantoprazole treatment at a mean dosage of 116 mg/day (range: 40-200 mg/day). Basal acid output was evaluated after each intragastric pH-metry, one hour before the next intake of proton pump inhibitor and a serum gastrin curve was determined according to 9 fixed time points.

Results: One patient dropped out before the second intragastric pH-metry due to an adverse event (varicella) unrelated to pantoprazole and was reinvestigated thereafter. The median 24-h intragastric pH with pantoprazole was not significantly different than that with the other proton pump inhibitors (5.3 versus 4.6, respectively; P=0.90). Neither the median basal acid output values nor the median serum gastrin levels were significantly different between pantoprazole and the other proton pump inhibitors.

Conclusion: In these patients with the Zollinger-Ellison syndrome, pantoprazole was well tolerated and equally effective to the other proton pump inhibitors in terms of antisecretory potency.

Publication types

  • Clinical Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents / therapeutic use*
  • Benzimidazoles / therapeutic use*
  • Female
  • Gastric Acid / metabolism*
  • Gastric Acidity Determination
  • Gastrins / blood
  • Humans
  • Lansoprazole
  • Male
  • Omeprazole / analogs & derivatives*
  • Omeprazole / therapeutic use
  • Pantoprazole
  • Prospective Studies
  • Proton Pump Inhibitors*
  • Sulfoxides / therapeutic use*
  • Time Factors
  • Zollinger-Ellison Syndrome / drug therapy*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Benzimidazoles
  • Gastrins
  • Proton Pump Inhibitors
  • Sulfoxides
  • Lansoprazole
  • Pantoprazole
  • Omeprazole